Are you Dr. Eary?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Uab Medical Center Jt N412 1 S
# 619
Birmingham, AL 35249Phone+1 205-934-3138
Summary
- Dr. Janet Eary, MD is a board certified nuclear medicine physician in Birmingham, Alabama. She is currently licensed to practice medicine in Alabama, Michigan, and Washington. She is affiliated with University of Alabama Hospital and is a Professor of Radiation Oncology at University Wash.
Education & Training
University of WashingtonResidency, Nuclear Medicine, 1983 - 1986- University of WashingtonResidency, Pathology-Anatomic and Clinical, 1980 - 1983
Michigan State University College of Human MedicineClass of 1980
Certifications & Licensure
WA State Medical License 1981 - 2026
MI State Medical License 2013 - 2017
AL State Medical License 2013 - 2016- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Pathology Anatomic Pathology & Clinical Pathology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Start of enrollment: 2008 Sep 01
- 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma Start of enrollment: 2010 Feb 01
- F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy Start of enrollment: 2010 Sep 15
Publications & Presentations
PubMed
- 12 citationsPredictors ofF-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.Esther Mena, Steven P Rowe, Joanna H Shih, Liza Lindenberg, Baris Turkbey
Journal of Nuclear Medicine. 2022-08-01 - 15 citations18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.Lanell M. Peterson, Brenda F. Kurland, Fengting Yan, Alena Novakova Jiresova, Vijayakrishna K. Gadi
Journal of Nuclear Medicine. 2021-02-01 - 1 citationsCancer Imaging Program Update: 2020.Janet F. Eary
Radiology. Imaging Cancer. 2020-07-31
Press Mentions
New Nuclear-Imaging Tests Show Promise in Locating CancerSeptember 25th, 2016
Grant Support
- Molecular Imaging Of Cancer And Its Response To TherapyNational Cancer Institute2011
- PET In Sarcoma - A Clinical TrialNational Cancer Institute2006–2011
- Lymphoma And Its Response To TreatmentNational Cancer Institute2004–2008
- Early Clinical Trials Of Imaging AgentsNational Cancer Institute2007
- PET In Sarcoma--A Clinical TrialNational Cancer Institute1995–2005
- Core--RadiochemistryNational Cancer Institute2000–2002
- Quantitation Of Tumor Growth In Novel Cancer TherapiesNational Cancer Institute1998–2002
- Radiolabelled Antibody Biodistribution, Internal Dosimetry/RadiotherapyNational Cancer Institute1995–1999
- Radiochemistry--CoreNational Cancer Institute1991–1999
- Determination Of Estrogen Receptor Content In Breast Cancer By PETNational Cancer Institute1996–1997
- Quantitation Of Radiolabeled Antibody DistributionNational Cancer Institute1989–1993
